XSHE
200028
Market cap1.57bUSD
Oct 09, Last price
12.00HKD
1D
0.59%
1Q
2.83%
Jan 2017
-66.44%
Name
China National Accord Medicines Corp Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China National Accord Medicines Corporation Ltd. focuses on the distribution of medical supplies and pharmaceuticals. Its broad product range encompasses traditional Chinese, biochemical, biological, and diagnostic medicines, as well as antibiotics and chemical preparations. The company also trades in food products, industrial chemicals, various general commodities, medical apparatus and instruments, glassware, cosmetics, daily merchandise, and offers wholesale and retail of health products. In addition to product sales, it provides a suite of services, including freight transportation, warehousing, loading and unloading, professional consultation, goods agency, technology import and export, and property leasing. As of December 31, 2021, the company operated a significant retail network of 8,798 drugstores, consisting of 7,257 directly owned and 1,541 franchised outlets, spanning 20 provinces, autonomous regions, and municipalities across China. Founded in 2004 and headquartered in Shenzhen, China, this entity functions as a subsidiary of Sinopharm Group Co., Ltd.
Key people
Yong Liu
Chairman of the Board · since 2017
Zhanjun Ma
Vice Chairman of the Board · since 2019
Xinyang Lin
Deputy General Manager · since 2005
Tianyao Liu
Deputy General Manager · since 2019
Director · since 2011
Director · since 2018
Honghui Chen
Independent Director · since 2017
Independent Director · since 2018
Headquarters & legal address
深圳市福田区八卦四路15号一致药业大厦
深圳市, GD 100000
CN
深圳市, GD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||